Drugs / Ortho-Cyclen
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02157467 | Jun → Aug 2014 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT01746732 | Dec 2012 → May 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01498861 | Dec 2011 → Mar 2012 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT01458210 | Oct 2011 → Feb 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01243580 Comparator | Aug → Dec 2009 | — | Agile Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00399685 Comparator | Dec 2006 → Aug 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT04039204 Comparator | Jan 2022 → Aug 2023 | endometriosis, infertility disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ortho-Cyclen | “Ortho-Cyclen (OC)” NCT01458210 ↗ |
| Route | Oral | “Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.” NCT00399685 ↗ |